US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

4.18

+0.02000.48%

Volume:26.82K

Turnover:110.78K

Market Cap:3.70M

PE:-0.06

High:4.26

Open:4.22

Low:4.07

Close:4.16

Loading ...

Overview Company News Filings

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Super League Enterprise Inc expected to post a loss of 33 cents a share - Earnings Preview

Super League Enterprise Closes Public Offering

MT Newswires Live

Press Release: Super League Enterprise, Inc. Announces the Closing of Underwritten Public Offering

BUZZ-U.S. STOCKS ON THE MOVE-Compass, Rumble, Tesla

US Stocks Higher; Lyft Posts Upbeat Earnings

Press Release: Super League Enterprise, Inc. Announces Pricing of Underwritten Public Offering

Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

BRIEF-Super League Enterprise Inc - Announces 35% Workforce Reduction

Press Release: Super League Announces Cost Structure Reductions Amid Drive Towards Profitability

Super League Enterprise Lays Off 35% of Workforce

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":4.18,"timestamp":1754417696396,"preClose":4.16,"halted":0,"volume":26815,"delay":0,"floatShares":811000,"shares":884699,"eps":-67.3644,"marketStatus":"Trading","change":0.02,"latestTime":"08-05 14:15:26 EDT","open":4.22,"high":4.26,"low":4.07,"amount":110778.25134900001,"amplitude":0.045673,"askPrice":4.18,"askSize":100,"bidPrice":4.09,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-67.3644,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1754424000000},"marketStatusCode":2,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.16,"preHourTrading":{"tag":"盘前","latestPrice":4.19,"preClose":4.16,"latestTime":"09:23 EDT","volume":58,"amount":242.71998340000002,"timestamp":1754400197964},"postHourTrading":{"tag":"盘后","latestPrice":4.23,"preClose":4.16,"latestTime":"19:04 EDT","volume":2427,"amount":10104.09,"timestamp":1754348665003},"volumeRatio":0.487582},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":811000,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-94.05048,"volumeRatio":0.487582,"shares":884699,"dividePrice":0,"high":4.26,"amplitude":0.045673,"preClose":4.16,"low":4.07,"week52Low":3.91,"pbRate":"-1.07","psRate":"0.25","week52High":53.2,"institutionHeld":0,"latestPrice":4.18,"committee":-0.818182,"eps":-67.3644,"divideRate":0,"volume":26815,"delay":0,"ttmEps":-67.3644,"open":4.22,"prevYearClose":24.7,"prevWeekClose":4.15,"prevMonthClose":4.3,"prevQuarterClose":4.635,"fiveDayClose":4.76,"twentyDayClose":5.85,"sixtyDayClose":13.016},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ITP","CLYM","BK4077","BK4199","CTA","SLE"],"gpt_icon":0},{"id":"2535744087","title":"Super League Enterprise Inc  expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2535744087","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535744087?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:47","pubTimestamp":1747169225,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of33cents a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to show a fall in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL2T4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Super League Enterprise Inc  expected to post a loss of 33 cents a share - Earnings Preview","news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2535202570","title":"Super League Enterprise Closes Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2535202570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535202570?lang=en_us&edition=fundamental","pubTime":"2025-05-13 00:57","pubTimestamp":1747069054,"startTime":"0","endTime":"0","summary":"Super League Enterprise  said Monday it has raised almost $870,000 from the sale of about 5.1 million shares at $0.17 a share in a public offering.The firm said it gave its underwriter a 45-day option to buy up to 767,647 additional shares. It plans to use the funds for general corporate needs, working capital, and debt repayment.Shares of the company were up about 8% in recent trading.Price: 0.16, Change: +0.01, Percent Change: +8.00","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2535220480","title":"Press Release: Super League Enterprise, Inc. Announces the Closing of Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2535220480","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535220480?lang=en_us&edition=fundamental","pubTime":"2025-05-13 00:25","pubTimestamp":1747067100,"startTime":"0","endTime":"0","summary":"SANTA MONICA, Calif., May 12, 2025  -- Super League Enterprise, Inc.  , a leader in redefining how brands connect with consumers through the power of playable media, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately $869,999, before deducting underwriting fees and other offering expenses payable by the Company.Aggregate gross proceeds to the Company were approximately $869,999, or expected to be $1 million if the over allotment option is exercised in full. The transaction closed on May 12, 2025. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital and the repayment of a portion of the Company's indebtedness.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2534459530","title":"BUZZ-U.S. STOCKS ON THE MOVE-Compass, Rumble, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2534459530","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534459530?lang=en_us&edition=fundamental","pubTime":"2025-05-10 01:57","pubTimestamp":1746813460,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Compass, Rumble, TeslaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL6N3RH0G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOM","HCI","HII","IDA","ONTO","ROK","COMP","EQR","EXPE","WBUYF","IP","OGS","PKG","CTVA","PODD","MCK","AHL","KINS","RUM","TOST","02018","GOGO","SLE","ESS","SOLV","EOG","NGVC","PAGP","PAA","AU","CVX","MCHP","GDOT","CPT","ANIP","APA","GXO","ZIP","NVVE","LYFT","AKAM","PRMB","NEM"],"gpt_icon":1},{"id":"2534710480","title":"US Stocks Higher; Lyft Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2534710480","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534710480?lang=en_us&edition=fundamental","pubTime":"2025-05-09 21:54","pubTimestamp":1746798840,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45318244/us-stocks-higher-lyft-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVVE","LYFT","NCNA","SYTA","SLE","DH","VEEE"],"gpt_icon":0},{"id":"2534845644","title":"Press Release: Super League Enterprise, Inc. Announces Pricing of Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2534845644","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534845644?lang=en_us&edition=fundamental","pubTime":"2025-05-09 21:00","pubTimestamp":1746795600,"startTime":"0","endTime":"0","summary":"SANTA MONICA, Calif., May 09, 2025  -- Super League Enterprise, Inc.  , a leader in redefining how brands connect with consumers through the power of playable media, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $869,999, before deducting underwriting fees and other offering expenses payable by the Company.Aggregate gross proceeds to the Company are expected to be approximately $869,999, or $1 million if the over allotment option is exercised in full. The transaction is expected to close on or about May 12, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital and the repayment of a portion of the Company's indebtedness.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2533184327","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184327?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:00","pubTimestamp":1746705600,"startTime":"0","endTime":"0","summary":"IND clearance and initiation of global basket trial exploring AlloNK + rituximab in refractory rheumatoid arthritis, Sjgren's disease, idiopathic inflammatory myopathies and systemic sclerosis. First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjgren's disease in the U.S.Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026. Dr. Aslan continued, \"Our longer-term aggressive B-NHL data is maturing into a leading data set, in line with approved auto-CAR-T therapies, providing proof of concept of AlloNK's ability to deplete B-cells deeply and durably. We remain well capitalized to gene","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","R","BK4232","BK4022","RA","ARTV","SLE"],"gpt_icon":0},{"id":"2533982344","title":"BRIEF-Super League Enterprise Inc - Announces 35% Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2533982344","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533982344?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:13","pubTimestamp":1746619992,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Enterprise Inc - Announces 35% Workforce ReductionSuper League Enterprise Inc SLE.O:SUPER LEAGUE ENTERPRISE INC - ANNOUNCES 35% WORKFORCE REDUCTIONSource text: ID:nGNX8XzVpgFurther company coverage: SLE.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF0GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2533710981","title":"Press Release: Super League Announces Cost Structure Reductions Amid Drive Towards Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2533710981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533710981?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:00","pubTimestamp":1746619200,"startTime":"0","endTime":"0","summary":"Company restructures executive compensation and reduces headcount to lower operating costs by approximately 30%. SANTA MONICA, Calif., May 07, 2025  -- Super League  , a leader in engaging audiences through playable media, content, and experiences, announced today an update on the Company's efforts to significantly reduce its costs structure through a 35% workforce reduction and restructuring of management compensation. The measures, effective primarily as of April 14, 2025 and May 1 , 2025, respectively, are expected to reduce fiscal year operating costs by approximately $2.7 million through December 31, 2025, which should help the Company reach its targeted goal of being EBITDA positive in Q4 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2533696983","title":"Super League Enterprise Lays Off 35% of Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2533696983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533696983?lang=en_us&edition=fundamental","pubTime":"2025-05-07 06:21","pubTimestamp":1746570060,"startTime":"0","endTime":"0","summary":"Super League Enterprise said it will undergo a 35% reduction in its workforce and a restructuring of management compensation.As of Dec. 31, the company had 75 full-time and full-time equivalent employees, according to a filing with the Securities and Exchange Commission. Based on that, the layoffs would affect about 26 people. The layoffs were effective April 14.The company said Tuesday the cost reduction measures were necessary for strategic realignment with industry consolidation trends.The company also said its executive chair, chief executive and chief financial officer agreed to a 10% reduction of their respective annual salaries beginning May 1.The measures will help the publisher of playable games reduce operating costs by about $2.7 million this year, which it said will help reach its targeted goal of being EBITDA positive in the fourth quarter.\"Today's announcement reinforces our commitment to streamlining the company's cost structure towards the goal of achieving profitabilit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2532810145","title":"RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810145","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810145?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting. H. pylori is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1]and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment represents a billion-dollar market opportunity[4]. RALEIGH, N.C., May 2, 2025 /PRNewswire/ --RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today announced its support of an independent medical education grant that includes a new two-part H. PyloriCME program, developed by Medscape and designed to advance clinical knowledge and improve patient outcomes. The first part of the program, a livestreamed event entitled \"Let's Get Social About H. pylori Management\" led by William Chey, MD, Vivian Asamoah, MD and Shailja Shah, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B42XCP33.USD","LU2506951875.HKD","MAA","LU0912757837.SGD","LU2089283258.USD","IE00BVYPNW00.USD","CME","BK4585","BK4144","LU0823417653.USD","BK4124","LU1481011911.USD","SLE","BK4588","LU0545562505.USD","LU0795875169.SGD","TEN","PPI","LU0795875086.SGD","LU0265550946.USD","LU2506952170.USD","LU0731783048.USD","LU0772969993.USD","LU1481011671.HKD","RDHL","UAE","LU1732800096.USD","LU2133065610.SGD","BK4112","LU2506951958.HKD","LU1509826696.USD","BK4215","IE0034235188.USD","LU2506952097.USD","LU1116320737.USD","IE00B3T34201.USD","IE00BVYPNV92.GBP","BK4121","LU1116320901.HKD","LU0823417737.USD","LU1718418525.SGD","BK4570","BK4007","SEER","LU0950375773.USD","LU0265550359.USD","LU1732799900.SGD","BK4077","LU0158827948.USD","LU1228905540.USD"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4200","BK4534","BK4588","SG9999001440.SGD","LU0289739699.SGD","LU2112291526.USD","BK4077","IE00BJT1NW94.SGD","LU0058720904.USD","TSLP","BK4233","MTA","PN","LU0889565916.HKD","SLE","LU1983299246.USD","LU1057294990.SGD","LU2242652126.USD","LU0868494617.USD","LU2242646821.SGD","MPA","IE00B2B36J28.USD","BK4205","BK4139","LU2468319806.SGD","LU1023059063.AUD","TCS","BK4096","LU2089984988.USD","BK4581","BK4599","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU1061106388.HKD","BK4188","BK4211","IE0009355771.USD","AMGN","BK4566","IE00B4R5TH58.HKD","LU0109394709.USD","IE0002141913.USD","BK4160","TCI","BK4585","GIPR","FCF"],"gpt_icon":0},{"id":"2532079789","title":"Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2532079789","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532079789?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"Acquisition further solidifies Super League as a leading provider of effective solutions that make brands playable within mobile games and the world’s largest immersive platforms. SANTA MONICA, Calif., May 01, 2025  -- Super League  , a leader in engaging audiences through playable media, content, and experiences, announced today the acquisition of Supersocial, an award-winning production studio and creative agency that has been a pioneer on the Roblox platform since its founding in 2020 by Yonatan Raz-Fridman , Pedro Romi, Luiza Justus, and Tatiana Wlasek. With this accretive acquisition, Super League expands its impressive roster of partnerships and reinforces the Company’s mission to connect brands with passionate consumer audiences through the power of play.Super League  is redefining how brands connect with consumers through the power of playable media. The Company provides global brands with ads, c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-acquires-supersocial-expanding-120000125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RBLX","BK4535","BK4554","BK4077","LU1861559042.SGD","BK4598","LU1861558580.USD","LU0348723411.USD","BK4551","BK4585","BK4085","BK4588","BK4565","SLE","BK4547"],"gpt_icon":0},{"id":"2531786662","title":"Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786662","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786662?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases. Sjgren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies. CAMBRIDGE, Mass., April 29, 2025  -- Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjgren’s disease  in the U.S. The Company previously received U.S. Food and Drug Administration  Investigational New Drug  Application clearance to study the CD19 T cell engager in patients with moderate to severe systemic lupus erythematosus  and European Medicines Agency  approval to study CLN-978 in active, difficult-to-treat rheumatoid arthritis.“There are an estimated four million Americans living with Sjgren’s disease, yet it is underdiagnosed","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-initiate-study-cln-110000913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","SLE","BK4139","BK4211","UBCP","BK4077","ACR","CGEM"],"gpt_icon":0},{"id":"2529412663","title":"Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2529412663","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529412663?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:05","pubTimestamp":1745438700,"startTime":"0","endTime":"0","summary":"Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia , lupus nephritis  and multiple sclerosis . Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus  support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025. Company plans to advance obe-cel in progressive forms of multiple sclerosis ; first patient expected to be dosed in Phase 1 trial by year-end 2025. LONDON, April 23, 2025  -- Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-highlights-advancing-autoimmune-200500705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","ALL","LU1162221912.USD","LU2347655156.SGD","LU1363072403.SGD","IE00B7SZL793.SGD","IE00BZ1G4Q59.USD","LU2133065610.SGD","LU0320765646.SGD","LENZ","LU0158827781.USD","LU1989772840.SGD","LU0267386448.USD","LU2065731478.USD","LU0106831901.USD","UCL","BK4139","LU2028103732.USD","LU0158827948.USD","LU1074936037.SGD","LU1732799900.SGD","LU2111349929.HKD","BK4504","LU0314104364.USD","BK4581","SLE","BK4516","IE0031619046.USD","LU0106261372.USD","BK4077","LU1668664300.SGD","CRS","LU0971096721.USD","LU1699723380.USD","BK4127","BK4022","BK4006","LU0795875169.SGD","LU2357305700.SGD","LU1571399168.USD","BK4107","AUTL","LU1720051017.SGD","LU0795875086.SGD","CAR","BK4585","LU2089284900.SGD","LU0912757837.SGD","BK4534","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2529668156","title":"Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668156?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:01","pubTimestamp":1745438460,"startTime":"0","endTime":"0","summary":"First U.S. patient dosed in ATALANTA-1 study of GLPG5101. Mantle cell lymphoma , a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028. Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo. Management to host conference call and webcast tomorrow, April 24, 2025, at 14:00 CET / 08:00 EDT. Mechelen, Belgium; April 23, 2025, 22:01 CET; regulated information – GalapagosNV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial and operational results for the first quarter of 2025.FIRST QUARTER 2025, RECENT BUSINESS UPDATE AND NEAR-TERM CATALYSTSClinical Pipeline: N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-first-quarter-2025-200100727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DM","BK4546","BK4077","GLPG","SLE","BK4161","BK4139"],"gpt_icon":0},{"id":"2527015440","title":"Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015440","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015440?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:42","pubTimestamp":1744728120,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis.The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.Year to date, shares of Fate Therapeutics have plunged 44% comp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-lupus-candidate-ft819-144200510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4007","IE00BN0W2V16.EUR","LU0889565916.HKD","BK4532","BK4077","FATE","LU0823416689.USD","KRYS","ADMA","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0109394709.USD","LU0320765992.SGD","BK4533","JAZZ","BK4139"],"gpt_icon":0},{"id":"2527549951","title":"Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549951","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549951?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:00","pubTimestamp":1744632000,"startTime":"0","endTime":"0","summary":"– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process. – RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study of FT819 in SLE. SAN DIEGO, April 14, 2025  -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell -derived off-the-shelf cellular immunotherapies to patients, today announced that the U.S. Food and Drug Administration  granted Regenerative Medicine Advanced Therapy  designation to FT819, an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis .The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies for serious","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-receives-regenerative-medicine-120000379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B7SZL793.SGD","BK4077","IE00B19Z4B17.USD","IE00B66KJ199.SGD","AEIS","FATE","IE0031619046.USD","SLE","BK4157"],"gpt_icon":0},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","IIM","RA","BK4139","ARTV","R","BK4077","BMS","SLE"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694232000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-08-04","current":-0.235277,"percent":0.674833,"low":-0.555206,"twenty":-0.336852,"median":-0.274262,"eighty":-0.211096,"high":-0.044016,"avg":-0.271788,"sd":0.100822,"marketCap":3671500},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-04","current":-0.235277,"twenty":-0.336852,"median":-0.274262,"eighty":-0.211096,"marketCap":3671500}],"updateTime":1754392620670}}}